METAMIZOLE: A REVIEW PROFILE OF A WELL-KNOWN "FORGOTTEN" DRUG. PART II: CLINICAL PROFILE

被引：35

作者：

Nikolova, Irina ^{[1
]}

Petkova, Valentina ^{[1
]}

Tencheva, Jasmina ^{[1
]}

Benbasat, Niko ^{[1
]}

Voinikov, Julian ^{[1
]}

Danchev, Nikolai ^{[1
]}

机构：

[1] Med Univ Sofia, Fac Pharm, Sofia, Bulgaria

来源：

BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT | 2013年 / 27卷 / 02期

关键词：

metamizole; NSAIDs; agranulocytosis; clinical trials; safety; efficacy; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LATIN-AMERICAN COUNTRIES; TENSION-TYPE HEADACHE; ACUTE-RENAL-FAILURE; DOUBLE-BLIND; INTRAVENOUS DIPYRONE; POSTOPERATIVE PAIN; ACETYLSALICYLIC-ACID; BLOOD DYSCRASIAS; ORAL MORPHINE;

D O I：

10.5504/BBEQ.2012.0135

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Part I of this review provided the pharmaceutical and non-clinical profile of rnetamizole, a non-narcotic analgesic with excellent analgesic and antipyretic effects. Metamizole is banned drug in many countries (United States, Japan, Australia, part of the European Union and nearly 30 other countries) for more than 40 years, where it is completely unknown or forgotten, while it is still freely available over-the-counter drug in many other countries, including Bulgaria. The drug's availability in oral and parenteral preparations has allowed its use in a range of clinical situations as monotherapy or in combination. It is known with different generic names, like metamizole, dipyrone, noramidopyrine, sulpyrine, novaminsulfon, methylmelubrin, etc. and marketed under hundreds of brand names worldwide. The objective of Part II of this review is to provide up-to-date scientific evidence for clinical safety and efficacy of the drug, as well as the place of metamizole in Bulgarian pharmaceutical market. Biotechnol. & Biotechnol. Eq. 2013, 27(2), 3605-3619

引用

页码：3605 / 3619

页数：15

共 103 条

[1] Population-based case-control study of the common cold during pregnancy and congenital abnormalities [J].